ENTA Enanta Pharmaceuticals Inc

Price (delayed)

$16.51

Market cap

$349.67M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.24

Enterprise value

$329.15M

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections ...

Highlights
ENTA's net income is down by 6% year-on-year but it is up by 4.7% since the previous quarter
The EPS has grown by 4.9% since the previous quarter but it has declined by 4.3% year-on-year
The debt has soared by 84% from the previous quarter and by 68% YoY
The equity has decreased by 38% YoY and by 13% from the previous quarter

Key stats

What are the main financial stats of ENTA
Market
Shares outstanding
21.18M
Market cap
$349.67M
Enterprise value
$329.15M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.1
Price to sales (P/S)
4.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.52
Earnings
Revenue
$72.88M
EBIT
-$118.76M
EBITDA
-$116.18M
Free cash flow
-$113.29M
Per share
EPS
-$6.24
Free cash flow per share
-$5.35
Book value per share
$7.85
Revenue per share
$3.44
TBVPS
$19.54
Balance sheet
Total assets
$413.56M
Total liabilities
$247.44M
Debt
$46.99M
Equity
$166.11M
Working capital
$296.42M
Liquidity
Debt to equity
0.28
Current ratio
6.43
Quick ratio
5.71
Net debt/EBITDA
0.18
Margins
EBITDA margin
-159.4%
Gross margin
100%
Net margin
-180.8%
Operating margin
-185.8%
Efficiency
Return on assets
-29.3%
Return on equity
-64.9%
Return on invested capital
-34.5%
Return on capital employed
-33.1%
Return on sales
-162.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ENTA stock price

How has the Enanta Pharmaceuticals stock price performed over time
Intraday
3.19%
1 week
20.69%
1 month
28.58%
1 year
-14.1%
YTD
75.45%
QTD
27.29%

Financial performance

How have Enanta Pharmaceuticals's revenue and profit performed over time
Revenue
$72.88M
Gross profit
$72.88M
Operating income
-$135.4M
Net income
-$131.74M
Gross margin
100%
Net margin
-180.8%
The net margin has contracted by 18% YoY but it has grown by 3.7% from the previous quarter
The operating margin has contracted by 17% YoY but it has grown by 3.7% from the previous quarter
The gross profit has contracted by 10% YoY
Enanta Pharmaceuticals's revenue has decreased by 10% YoY

Growth

What is Enanta Pharmaceuticals's growth rate over time

Valuation

What is Enanta Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.1
P/S
4.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.52
The EPS has grown by 4.9% since the previous quarter but it has declined by 4.3% year-on-year
The equity has decreased by 38% YoY and by 13% from the previous quarter
ENTA's P/B is 28% above its last 4 quarters average of 1.6 but 18% below its 5-year quarterly average of 2.5
The price to sales (P/S) is 47% lower than the 5-year quarterly average of 8.8 but 13% higher than the last 4 quarters average of 4.1
Enanta Pharmaceuticals's revenue has decreased by 10% YoY

Efficiency

How efficient is Enanta Pharmaceuticals business performance
Enanta Pharmaceuticals's return on equity has shrunk by 60% YoY and by 7% QoQ
Enanta Pharmaceuticals's ROA has increased by 16% YoY and by 9% from the previous quarter
ENTA's return on invested capital is up by 15% year-on-year and by 13% since the previous quarter
The return on sales has grown by 6% since the previous quarter but it has declined by 6% year-on-year

Dividends

What is ENTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ENTA.

Financial health

How did Enanta Pharmaceuticals financials performed over time
The company's total assets is 67% higher than its total liabilities
The company's total assets rose by 27% YoY but it fell by 3.5% QoQ
Enanta Pharmaceuticals's current ratio has decreased by 24% YoY but it has increased by 2.9% from the previous quarter
The debt is 72% less than the equity
The company's debt to equity has surged by 180% YoY and by 115% QoQ
The debt has soared by 84% from the previous quarter and by 68% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.